2026 Webinar – Viral Hepatitis and Sexual Health in LBGTQ+ Communities and Beyond

Create Account

Availability

Registration Required

Online Meeting

Jun 09, 2026 12:00 PM - 1:00 PM ET

Cost

$0.00

Credit Offered

No Credit Offered

Description
Learning Objectives
Faculty and Disclosures

LGBTQ+ populations, especially MSM and transgender people, remain disproportionately affected by viral hepatitis risk, yet these topics are often underemphasized in hepatology education. Furthermore, because the broader public-health information environment has become less stable for public-health information environment has become less stable for LGBTQ+ focused content. Multiple current CDC webpages regarding this topic has been modified or removed. In this environment, hepatology providers need a trusted, specialty-based educational forum to review evidence, clarify best practices and discuss stigma-free, prevention-focused care for LGBTQ+ people. Faculty discussions and expert experience further support the need for practical education on affirming sexual health conversations, hepatitis A vaccination, Hepatitis B prevention in the setting of PrEP, and Hepatitis C transmission and elimination strategies in MSM and transgender communities.

COPYRIGHT: All faculty in this activity have given their permission for publication ©2026 AASLD.

Upon completion of this activity, a participant should be able to:

Describe how clinicians provide stigma-free, affirming sexual healthcare while addressing viral hepatitis prevention in sexual and gender minorities
Identify HBV-related issues in the SGM population, including PrEP use
Discuss HCV elimination and education strategies in MSM and transgender populations

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Moderators and Faculty:

Ronni Marks

Nitzan Roth, MD, PhD
Nothing to Disclose

Tzu-Hao Howard Lee, MD
Scientific Consultant/Advisor: AbbVie

Kaitlin Malick-Petschulat, NP
Nothing to Disclose

Jessica Wisocky, NP, MSN
Scientific Consultant/Advisor: Guidepoint Global

Elizabeth Goacher, PA-C, MHS, AF-AASLD
Scientific Consultant/Advisor: Salix, GlaxoSmithKline, Madrigal, Ipsen, Mirum, Gilead, Boehringer Ingelheim

Reviewers and Staff:

Nikroo Hashemi, MD, MPH
Nothing to Disclose

Martin Moehlin, MD, MPH
Scientific Consultant/Advisor: Madrigal, Ipsen
Commercial Speakers Bureau: Gilead, Intercept

Renumathy Dhanasakarn, MD, PhD
Research Grants: NIIH, American College of Gastroenterology